Cabozantinib and Pembrolizumab in Metastatic Pancreas
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Pancreatic Cancer
DRUG: Cabozantinib|DRUG: Pembrolizumab
Progression-free survival, Progress-free survival in participants, defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever comes first., 1 year
Change in overall response to therapy, The proportion of participants with overall response to therapy via imaging, 2 months, 4 months, 6 months, 9 months, 12 months|Complete response, The proportion of participants with a complete response to therapy, 1 year|Partial response, The proportion of participants with a partial response to therapy, 1 year|Overall participant survival rate, Overall survival rate participants, 1 year
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.